CLOs on the Move

iMedicor

www.imedicor.com

 
iMedicor, Inc. is a national provider of comprehensive secure communications solutions for the medical and dental communities. iMedicor offers dentists, general practitioners, specialized doctors and other healthcare professionals the use of a secure, HIPAA-compliant communications network that addresses current federal standards for security and interoperability. iMedicor also serves as one of the country's leading Meaningful Use consultants to assist doctors and dentists with conversion from paper to electronic health records (EHRs) and qualify under Medicare and Medicaid guidelines for Federal Incentive Funding.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.imedicor.com
  • 523 Avalon Gardens Dr
    Nanuet, NY USA 10954
  • Phone: 888.994.4722

Executives

Name Title Contact Details

Similar Companies

Whiteball Boca Raton

Whiteball Boca Raton is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Boca Raton, FL. To find more information about Whiteball Boca Raton, please visit www.whitehallboca.com

Most Products Inc

Most Products Inc is a Plainwell, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Enochian BioSciences

Enochian BioSciences (formerly DanDrit Biotech USA Inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for HIV/AIDS and cancer.

Surface Oncology

Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.

Kronus

Kronus is a Boise, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.